| Five-year outcomes of magnetic resonance imaging–based active surveillance for prostate cancer: a large cohort study V Stavrinides, F Giganti, B Trock, S Punwani, C Allen, A Kirkham, ... European urology 78 (3), 443-451, 2020 | 121 | 2020 |
| What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort JM Norris, LMC Echeverria, SRJ Bott, LC Brown, N Burns-Cox, ... European urology 78 (2), 163-170, 2020 | 85 | 2020 |
| Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort F Giganti, A Stabile, V Stavrinides, E Osinibi, A Retter, C Orczyk, ... European radiology 31, 1644-1655, 2021 | 50 | 2021 |
| Outcome in surgically treated Rathke's cleft cysts: long-term monitoring needed R Trifanescu, V Stavrinides, P Plaha, S Cudlip, JV Byrne, O Ansorge, ... European Journal of Endocrinology 165 (1), 33-37, 2011 | 50 | 2011 |
| MRI in active surveillance: a critical review V Stavrinides, F Giganti, M Emberton, CM Moore Prostate cancer and prostatic diseases 22 (1), 5-15, 2019 | 48 | 2019 |
| Stroma in normal and cancer wound healing E Huet, C Jaroz, HQ Nguyen, Y Belkacemi, A de la Taille, V Stavrinides, ... The FEBS Journal 286 (15), 2909-2920, 2019 | 36 | 2019 |
| Orchidopexy for testicular torsion: a systematic review of surgical technique SL Moore, R Chebbout, M Cumberbatch, J Bondad, L Forster, J Hendry, ... European urology focus 7 (6), 1493-1503, 2021 | 34 | 2021 |
| The oncogene metadherin interacts with the known splicing proteins YTHDC1, Sam68 and T-STAR and plays a novel role in alternative mRNA splicing HJ Luxton, BS Simpson, IG Mills, NR Brindle, Z Ahmed, V Stavrinides, ... Cancers 11 (9), 1233, 2019 | 33 | 2019 |
| Image quality assessment for machine learning tasks using meta-reinforcement learning SU Saeed, Y Fu, V Stavrinides, ZMC Baum, Q Yang, M Rusu, RE Fan, ... Medical Image Analysis 78, 102427, 2022 | 28 | 2022 |
| Cellular senescence as a possible link between prostate diseases of the ageing male G Fiard, V Stavrinides, ES Chambers, S Heavey, A Freeman, R Ball, ... Nature Reviews Urology 18 (10), 597-610, 2021 | 26 | 2021 |
| Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study F Giganti, M Pecoraro, V Stavrinides, A Stabile, S Cipollari, A Sciarra, ... European Radiology 30, 2082-2090, 2020 | 25 | 2020 |
| False positive multiparametric magnetic resonance imaging phenotypes in the biopsy-naïve prostate: are they distinct from significant cancer-associated lesions? Lessons from PROMIS V Stavrinides, T Syer, Y Hu, F Giganti, A Freeman, S Karapanagiotis, ... European urology 79 (1), 20-29, 2021 | 24 | 2021 |
| Evaluation of PSA and PSA density in a multiparametric magnetic resonance imaging-directed diagnostic pathway for suspected prostate cancer: the INNOVATE trial H Pye, S Singh, JM Norris, LM Carmona Echeverria, V Stavrinides, A Grey, ... Cancers 13 (8), 1985, 2021 | 15 | 2021 |
| Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance A Tomer, D Nieboer, MJ Roobol, A Bjartell, EW Steyerberg, D Rizopoulos, ... BJU international 127 (1), 96-107, 2021 | 14 | 2021 |
| Prostate cancer measurements on serial MRI during active surveillance: it’s time to be PRECISE F Giganti, V Stavrinides, A Stabile, E Osinibi, C Orczyk, JP Radtke, ... The British Journal of Radiology 93 (1116), 20200819, 2020 | 14 | 2020 |
| Prostate cancer patients under active surveillance with a suspicious magnetic resonance imaging finding are at increased risk of needing treatment: results of the Movember … J Olivier, W Li, D Nieboer, J Helleman, M Roobol, V Gnanapragasam, ... European Urology Open Science 35, 59-67, 2022 | 13 | 2022 |
| When no treatment is the best treatment: active surveillance strategies for low risk prostate cancers V Stavrinides, CC Parker, CM Moore Cancer treatment reviews 58, 14-21, 2017 | 12 | 2017 |
| Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models V Stavrinides, G Papageorgiou, D Danks, F Giganti, N Pashayan, B Trock, ... Prostate Cancer and Prostatic Diseases 24 (4), 1028-1031, 2021 | 11 | 2021 |
| Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI‐characterized prostates J Olivier, V Stavrinides, J Kay, A Freeman, H Pye, Z Ahmed, ... The Prostate 78 (16), 1229-1237, 2018 | 11 | 2018 |
| Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease? F Giganti, C Allen, V Stavrinides, A Stabile, A Haider, A Freeman, ... The British Journal of Radiology 95 (1131), 20210321, 2022 | 8 | 2022 |
Mark EmbertonProfessor of Interventional Oncology, University College London, UK在 ucl.ac.uk 的电子邮件经过验证
